Merger Arbitrage Mondays - 5 New Multi-Billion Dollar Deals seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
dMY Technology Group, Inc. II (NYSE: DMYD)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of
dMY Technology Group, Inc. II (NYSE: DMYD) in connection with the company s proposed merger with Genius Sports Group Limited ( GSG ). Under the terms of the agreement, DMYD will acquire GSG through a reverse merger that will result in GSG becoming a public company. If you own DMYD shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:
Eidos Therapeutics, Inc. (NASDAQ: EIDX)
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)
concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities.
If you are a Cellular Biomedicine shareholder,
.
Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm
free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)
Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CBMG to members of CBMG management.
If you are a CBMG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780.
Cleveland BioLabs, Inc. (NASDAQ: CBLI)
Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of CBLI with Cytocom.
If you are a CBLI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
Share this article
Share this article
SANTA CLARA, Calif., Dec. 15, 2020 /PRNewswire/ Marvell Technology Group Ltd. (NASDAQ: MRVL) ( Marvell ), a leading provider of data infrastructure semiconductor solutions, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ( HSR Act ), as amended, in connection with its previously announced proposed acquisition of Inphi Corporation ( Inphi ), expired at 11:59 p.m. EST on December 14, 2020.
The expiration of the HSR Act waiting period satisfies one of the conditions to the closing of the proposed acquisition, which remains subject to other customary closing conditions, including receipt of shareholder approvals and other regulatory approvals.